Presence of Endometrioma Decreased Blastocyst Formation Rate but Not Impair Assisted Reproductive Technology (ART) outcome

Jui‐Chun Chang, Yu‐Chiao Yi, Ya‐Fang Chen, Hwa-Fen Guu, Hsiao-Fan Kung, Liyu Chen, Shih-Ting Chuan, Ming-Jer Chen
In: Research Square · 2022 · doi:10.21203/rs.3.rs-2329900/v1 · W4313272313
preprint OA: green CC0
📄 Open PDF View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Endometrioma presence reduced blastocyst formation but did not negatively impact cumulative live birth rates in patients undergoing assisted reproductive technology.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-08 ⓘ

This retrospective study assessed whether having an ovarian endometrioma affects IVF/ICSI outcomes in women ≤40 years who sought treatment for endometriosis at an academic center between 2014 and 2020, comparing 208 IVF/ICSI cycles with endometrioma or endometriosis to 624 matched cycles without endometriosis. Women were further categorized by endometrioma status (primary, recurrent after cystectomy, and status post cystectomy with no endometrioma during IVF/ICSI), and outcomes including blastocyst formation rate and cumulative live birth rate (CLBR) through fresh and/or subsequent FET were analyzed; the authors note that live birth prediction depended on covariates like age, total FSH dose, and blastocyst formation rate. The endometrioma subgroup had a significantly lower blastocyst formation rate than the endometriosis and control groups, but CLBRs were comparable across groups, and cystectomy did not alter IVF/ICSI outcomes when ovarian reserve was comparable, with recurrent endometrioma not worsening outcomes versus primary endometrioma. This paper is centrally about endometriosis — it evaluates how endometrioma presence and cystectomy history influence ART/IVF outcomes in women with endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Abstract Purpose : These study aims to assess the impact of endometrioma on patients who undergo ART treatment due to endometriosis. Methods : Retrospective study was conducted in women ≤ 40 years of age who underwent ART treatment at an academic medical center between January 2014 and December 2020. Two-hundred-and-eight women had received IVF/ICSI treatment due to endometriosis and there were 89 patients’ presence of endometrioma. Patients were further divided into primary endometrioma, recurrent endometrioma and those having received cystectomy for endometrioma prior to IVF/ICSI. The control group included 624 infertile women without endometriosis. Results : In the endometrioma subgroup (B) the blastocyst formation rate was significantly lower when compared with the endometriosis (A) and control groups (C). The cumulative live birth rates (CLBRs) (60.5% versus 49.4% versus 56.9%, p=0.194 in A versus B, p=0.406 in A versus C, p=0.878 in B versus C) were comparable. Multiple logistic regression analysis revealed that female age, total FSH dose and blastocyst formation rate were the significant variables in predicting CLBR (OR: 0.89, CI: 0.80–0.99, p < 0.025, OR:0.68 CI:0.53-0.88, p=0.003 and OR: 30.04, CI: 9.93–90.9, p < 0.001, respectively). The CLBRs were comparable 47.1%, 60% and 57.9% in the primary endometrioma, s/p cystectomy and recurrent endometrioma group . Conclusion: Although the blastocyst formation rate was lower in the endometrioma group, CLBR was not worse than those who were in the endometriosis or control group. Cystectomy for endometrioma did not alter IVF/ICSI outcomes if ovarian reserve was comparable. Recurrent endometrioma did not worsen IVF/ICSI outcomes than primary endometrioma.

My notes (saved in your browser only)

Condition tags

endometriosisendometrioma

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (40)

Source provenance

europepmc
last seen: 2026-06-11T06:38:44.028908+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK